See the DrugPatentWatch profile for bupivacaine
Liposomal bupivacaine is an injectable, long-acting local anesthetic used to manage postoperative pain [1][2]. It is a formulation of bupivacaine, an amide-type local anesthetic, encapsulated within multivesicular liposomes [1][3]. This delivery system allows for the extended release of bupivacaine, providing analgesia for up to 72 hours after a single administration [2][3].
How does liposomal bupivacaine provide extended pain relief?
The liposomal formulation is designed for sustained release of the active drug, bupivacaine [1][3]. The drug is encapsulated in a lipid bilayer structure that gradually breaks down, releasing bupivacaine over an extended period [3]. This contrasts with immediate-release bupivacaine solutions, which are quickly metabolized and cleared, resulting in shorter duration of action [2]. The multivesicular liposomes create a reservoir of the anesthetic that is slowly released into the surrounding tissues [3].
What are the uses of liposomal bupivacaine?
Liposomal bupivacaine is indicated for administration into the surgical site to provide local analgesia [1][2]. It is approved for various surgical procedures, including orthopedic surgeries, general surgeries, and obstetric procedures [1]. It is administered via infiltration at the surgical site, offering pain management directly where surgery was performed [3].
What are the potential side effects of liposomal bupivacaine?
Common side effects associated with liposomal bupivacaine use include nausea, constipation, vomiting, headache, fever, and dizziness [2]. More serious adverse events can occur, such as neurological effects (e.g., paresthesia, hypesthesia, numbness) and cardiovascular effects (e.g., bradycardia, hypotension, cardiac arrest) if the drug is unintentionally injected intravascularly [2]. Patients with severe liver disease may also be at increased risk [2].
When does the patent for liposomal bupivacaine expire?
Information on the specific patent expiry dates for liposomal bupivacaine products can be found through patent tracking resources. DrugPatentWatch.com tracks patents and exclusivity for pharmaceutical products, offering details on when patents are set to expire, which can indicate when generic or biosimilar competition might emerge [4].
Are there alternatives to liposomal bupivacaine for pain management?
Alternatives to liposomal bupivacaine for postoperative pain management include traditional local anesthetics, epidural anesthesia, nerve blocks, and systemic analgesics such as opioids and non-opioid pain relievers [5]. The choice of pain management strategy depends on the type of surgery, patient factors, and desired duration of pain relief [5].
What is the mechanism of action of bupivacaine?
Bupivacaine, the active component in liposomal bupivacaine, functions by reversibly blocking nerve impulse conduction [1]. It achieves this by inhibiting sodium ion influx across the neuronal membrane, thus preventing depolarization and the generation of an action potential [1]. This blockade leads to a loss of sensation in the area where it is applied.